BC Innovations | Oct 25, 2018
Distillery Therapeutics


INDICATION: Pain Rat studies suggest promoting the expression of TRESK or inhibiting its negative regulators VEGF and VEGFR2 could help treat pain associated with bone metastasis. In a rat model of bone metastasis-associated pain, TRESK...
BC Innovations | Dec 19, 2013
Translation in Brief

Translational tidbits

Consorting with academia GlaxoSmithKline plc has set up an immuno-oncology consortium that invites academics from six cancer centers to view its nonpublic early pipeline programs and share ideas for new therapeutic candidates. The Oncology Clinical...
BC Week In Review | Nov 18, 2013
Company News

MRC, University of Oxford deal

MRC Technology, the U.K.'s MRC Technologies’s technology transfer organization, partnered with the university to screen selective and potent potassium channel K2p18.1 ( KCNK18 ; TRESK ) activators to develop compounds to treat migraines. According to the partners,...
BC Innovations | Oct 7, 2010
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Migraine Potassium channel K2p18.1 (KCNK18; TRESK) In vitro and patient sample studies suggest that TRESK agonists could help prevent or...
Items per page:
1 - 4 of 4